Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct 23;8(10):e76477.
doi: 10.1371/journal.pone.0076477. eCollection 2013.

Non-pneumatic anti-shock garment (NASG), a first-aid device to decrease maternal mortality from obstetric hemorrhage: a cluster randomized trial

Suellen Miller  1 , Eduardo F Bergel, Alison M El Ayadi, Luz Gibbons, Elizabeth A Butrick, Thulani Magwali, Gricelia Mkumba, Christine Kaseba, N T My Huong, Jillian D Geissler, Mario Merialdi
Affiliations
Randomized Controlled Trial

Non-pneumatic anti-shock garment (NASG), a first-aid device to decrease maternal mortality from obstetric hemorrhage: a cluster randomized trial

Suellen Miller et al. PLoS One. .

Abstract

Background: Obstetric hemorrhage is the leading cause of maternal mortality. Using a cluster randomized design, we investigated whether application of the Non-pneumatic Anti-Shock Garment (NASG) before transport to referral hospitals (RHs) from primary health care centers (PHCs) decreased adverse outcomes among women with hypovolemic shock. We hypothesized the NASG group would have a 50% reduction in adverse outcomes.

Methods and findings: We randomly assigned 38 PHCs in Zambia and Zimbabwe to standard obstetric hemorrhage/shock protocols or the same protocols plus NASG prior to transport. All women received the NASG at the RH. The primary outcomes were maternal mortality; severe, end-organ failure maternal morbidity; and a composite mortality/morbidity outcome, which we labeled extreme adverse outcome (EAO). We also examined whether the NASG contributed to negative side effects and secondary outcomes. The sample size for statistical power was not reached; of a planned 2400 women, 880 were enrolled, 405 in the intervention group. The intervention was associated with a non-significant 46% reduced odds of mortality (OR 0.54, 95% CI 0.14-2.05, p = 0.37) and 54% reduction in composite EAO (OR 0.46, 95% CI 0.13-1.62, p = 0.22). Women with NASGs recovered from shock significantly faster (HR 1.25, 95% CI 1.02-1.52, p = 0.03). No differences were observed in secondary outcomes or negative effects. The main limitation was small sample size.

Conclusions: Despite a lack of statistical significance, the 54% reduced odds of EAO and the significantly faster shock recovery suggest there might be treatment benefits from earlier application of the NASG for women experiencing delays obtaining definitive treatment for hypovolemic shock. As there are no other tools for shock management outside of referral facilities, and no safety issues found, consideration of NASGs as a temporizing measure during delays may be warranted. A pragmatic study with rigorous evaluation is suggested for further research.

Trial registration: ClinicalTrials.gov NCT00488462.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Non-pneumatic Anti-Shock Garment (NASG) Photo.
A model in an NASG.
Figure 2
Figure 2. Schematic of the NASG.
This figure shows an opened NASG. The articulated leg segments (1, 2, 3) are attached to the pelvic segment (4), and the abdominal segments (5, 6) contain a foam ball for extra pressure.
Figure 3
Figure 3. Cluster Randomized Trial Design.
See this image and copyright information in PMC

References

    1. Lozano R, Wang H, Foreman KJ, Rajaratnam JK, Naghavi M, et al. (2011) Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet 378: 1139–1165. - PubMed
    1. WHO (2012) WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization. 42 p. - PubMed
    1. Lalonde A (2012) Prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynaecol Obstet 117: 108–118. - PubMed
    1. Mobeen N, Durocher J, Zuberi N, Jahan N, Blum J, et al. (2010) Use of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage during home deliveries in Pakistan: a randomised placebo-controlled trial. British Journal of Obstetrics and Gynaecology 118: 353–361. - PMC - PubMed
    1. Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, et al. (2006) Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 368: 1248–1253. - PubMed

Publication types

Associated data